Skip to content Skip to footer
Cytonics Corporation
Cytonics Corporation
Cytonics Corporation
Close

#54 🌿 The Beauty of Nature’s Design

June 26, 2025713Views
Cytonics is developing innovative therapies for osteoarthritis by leveraging Alpha-2-Macroglobulin (A2M), a natural protein that combats harmful enzymes. The initial success of their device, APIC™, led to the creation of CYT-108, a more potent and consistent engineered version of A2M, aimed at addressing the root causes of cartilage degradation.

Read More

#53 🧪 The Experiment That Started It All

June 25, 2025691Views
The journey of developing a cartilage-protecting therapy began with a hypothesis about the A2M protein’s potential. Initial experiments showed A2M could significantly reduce cartilage destruction caused by osteoarthritis. This led to the creation of APIC™ and the more advanced CYT-108, which demonstrated remarkable efficacy in preclinical trials, paving the way for human clinical trials.

Read More

#50🔊Listen To Our CEO Describe Our Science In 40 Seconds

May 27, 2025652Views
Cytonics has released a video featuring CEO Joey Bose, explaining how their therapy CYT-108 challenges Big Pharma by targeting osteoarthritis’s root causes, rather than just symptoms. The video discusses past successes with APIC, the science behind their approach, and future strategies. Viewers are encouraged to support the company as potential shareholders.

Read More

#49 🦈 When a Shark Asks the Right Questions

May 14, 2025825Views
Cytonics CEO Joey Bose discussed their groundbreaking approach to osteoarthritis with investor Kevin O’Leary. The biotech firm has treated over 10,000 patients and developed a therapy, CYT-108, which has completed Phase 1 trials. With $15M raised from 6,000 everyday investors, Cytonics challenges traditional Big Pharma funding models.

Read More

Cytonics Announces Initiation Of First-In-Human Phase 1 Clinical Study For CYT-108 In Patients Suffering From Osteoarthritis Of The Knee

April 22, 20251KViews
JUPITER, Fla., July 15, 2024 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing biologic therapies for musculoskeletal ailments, today announced initiation of enrollment for its Phase 1 clinical study of CYT-108, a recombinant variant of the alpha-2-macroglobulin blood serum protein, targeting proteases responsible for cartilage degradation in osteoarthritis (OA). CYT-108 was engineered for increased…

Read More

Cytonics Announces Completion Of Enrollment For Phase 1 Clinical Study Evaluating CYT-108, A Novel Recombinant Protease Inhibitor, In Patients Suffering From Osteoarthritis Of The Knee

April 22, 2025971Views
Top-line results from Phase 1 study expected in second quarter of 2025 JUPITER, Fla., Sept. 6, 2024 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing biologic therapies for inflammatory musculoskeletal conditions, today announced completion of enrollment for their Phase 1 clinical study of CYT-108, a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor, as…

Read More

Cytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial

April 22, 20251KViews
– No adverse events reported; CYT-108 progressing as a potential disease-modifying therapy for osteoarthritis – JUPITER, Fla., Jan. 21, 2025 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing cutting-edge biologic therapies for musculoskeletal conditions, today announced that the first nine patients in its Phase 1 clinical trial evaluating CYT-108 as a therapy for osteoarthritis have…

Read More

Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

April 22, 20251KViews
Cytonics Seeks $24 million to pursue FDA Phase 2 Clinical Study of CYT-108, the Company's Novel Therapy for Osteoarthritis JUPITER, Fla., March 25, 2025 /PRNewswire/ -- Cytonics today announced that it is launching an offering of securities through the use of an offering statement that has been qualified by the Securities and Exchange Commission. Cytonics has partnered…

Read More

#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development

March 25, 2025638Views
Cytonics is seeking $24 million to fund a Phase 2 Clinical Study for CYT-108, its innovative osteoarthritis therapy. This fundraising effort, in partnership with StartEngine, utilizes Regulation A+, allowing unaccredited investors to participate. CYT-108 offers unique protease inhibition benefits and builds on the success of its predecessor, the APIC system.

Read More

Marketing by Katapult Marketing
© 2026 Cytonics Corporation – All rights reserved

Get fresh updates
Subscribe

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 30 East 23rd Street, 2nd Floor, NY, NY 10010, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA’s BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Receive News

Download Exclusive Investor Presentation & Stay Updated

Name(Required)
Privacy(Required)